Xontogeny

News

Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP

Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies

Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups

Quellis Biosciences Inc. Announces $17 Million Series A Financing

Landos Biopharma Completes $60 Million Series B Financing